Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 83 of 1,261
  1. US 12139487

    Compounds and uses thereof

    FOGHORN THERAPEUTICS INC. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  2. US 12139543

    Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR

    CytomX Therapeutics, Inc. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  3. US 12139546

    Methods of treating urea cycle disorders by interfering with glucagon receptor signaling

    REGENERON PHARMACEUTICALS, INC. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  4. US 12139709

    Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

    Sarepta Therapeutics, Inc. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  5. US 12138325

    Dental composition

    KURARAY NORITAKE DENTAL INC. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  6. US 12138243

    Antiviral use of FABP4 modulating compounds

    CRESCENTA BIOSCIENCES Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  7. US 12139486

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  8. US 12138272

    Methods and compositions for treating amyotrophic lateral sclerosis

    Amylyx Pharmaceuticals, Inc. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  9. US 12138276

    Halogenated psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  10. US 12139711

    Antisense oligonucleotides for the treatment of Leber congenital amaurosis

    Stichting Radboud universitair medisch centrum Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  11. US 12138301

    Compounds including a mutant KRAS sequence and a lipid and uses thereof

    Elicio Therapeutics, Inc. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  12. US 12138294

    Transgenic corn with antifungal peptide AGM182 (DN:0113.18)

    The United States of America, as represented by the Secretary of Agriculture Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  13. US 12139499

    Heteroaryl compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  14. US 12138233

    Methods of treating idiopathic hypersomnia

    Jazz Pharmaceuticals Ireland Limited Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  15. US 12138263

    Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  16. US 12138247

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  17. US 12139470

    Trioxolane agents

    The Regents of the University of California Β· Granted Nov 12, 2024 Β· Expires Nov 7, 2044

    granted
  18. US 2024368250

    POLYPEPTIDES BINDING TO THE NEONATAL FC RECEPTOR

    ABLYNX NV [BE] Β· Granted Nov 7, 2024 Β· Expires Nov 2, 2044

    granted
  19. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. Β· Granted Nov 5, 2024 Β· Expires Oct 31, 2044

    granted
  20. US 12134609

    Quinoline cGAS antagonist compounds

    The Board of Regents of the University of Texas System Β· Granted Nov 5, 2024 Β· Expires Oct 31, 2044

    granted
  21. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. Β· Granted Nov 5, 2024 Β· Expires Oct 31, 2044

    granted
  22. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. Β· Granted Nov 5, 2024 Β· Expires Oct 31, 2044

    granted
  23. US 12133924

    Compositions and methods for organ specific delivery of nucleic acids

    The Board of Regents of the University of Texas System Β· Granted Nov 5, 2024 Β· Expires Oct 31, 2044

    granted
  24. US 12133856

    Multi-substituent psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. Β· Granted Nov 5, 2024 Β· Expires Oct 31, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.